Skip to main content

Table 2 Adverse events related to the study treatment

From: A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma

Adverse event

NCI common toxicity criteria grade

 

1

2

3

4

Any (%)

Total

Neutropenia

5

4

1

4

14 (30)

42

Thrombocytopenia

19

8

1

2

30 (71)

42

Anaemia

13

17

8

2

40 (95)

42

Infection

16

8

5

0

29 (67)

43

Vomiting

11

4

3

0

18 (43)

42

Diarrhoea

14

7

4

0

25 (58)

43

Dyspnoea

3

11

5

2

21 (49)

43

Fatigue

13

14

12

1

40 (93)

43

Neuropathy

19

2

0

0

21 (49)

43

Allergy

5

0

0

1

6 (14)

43

Alopecia

11

26

0

0

37 (88)

42

Joint pain

15

9

0

0

24 (56)

43